Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May 8:9:138.
doi: 10.1186/1471-2407-9-138.

Delta-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients

Thissiane L Gonçalves  1 , Dalila M Benvegnú, Gabriela Bonfanti, Andressa V Frediani, João Batista T Rocha
Affiliations

Delta-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients

Thissiane L Gonçalves et al. BMC Cancer. .

Abstract

Background: Bone marrow transplantation (BMT) is often used in the treatment of various diseases. Before BMT, patients are submitted to a conditioning regimen (CR), which consists of the administration of high doses of chemotherapy. The action of many cytostatic drugs involves the overproduction of reactive oxygen species, which together with inadequate antioxidant protection can lead to oxidative stress and this has been implicated in the etiology of various diseases. The objectives of this study were to look for evidence of oxidative stress and also to analyze delta-Aminolevulinato dehydratase (delta-ALA-D) activity as a possible marker of oxidative stress in autologous and allogeneic BMT patients.

Methods: Lipid peroxidation, vitamin C and thiol group levels as well as catalase, superoxide dismutase and delta-ALA-D activity were determined in 37 healthy controls, 13 patients undergoing autologous peripheral blood stem cell transplantation and 24 patients undergoing allogeneic BMT.

Results: We found that patients presented signs of oxidative stress before they were submitted to BMT, during CR and up to 20 days after BMT. There was a decrease in enzymatic and non enzymatic antioxidant defenses, in delta-ALA-D activity, and an increase in lipoperoxidation in the blood of both patient groups.

Conclusion: This study has indicated that autologous and allogeneic BMT are associated with oxidative stress. Moreover, blood delta-ALA-D activity seems to be an additional biomarker of oxidative stress in BMT patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Erythrocyte catalase (CAT) activity over time. CR: conditioning regimen; BMT: bone marrow transplantation. Data are expressed as median (lower/upper quartile). Group I (n = 37); Group II (n = 13); Group III (n = 24).a Significantly different from group I (control), dsignificantly different from CR.
Figure 2
Figure 2
Erythrocyte superoxide dismutase (SOD) activity over time. CR: conditioning regimen; BMT: bone marrow transplantation. Data are expressed as median (lower/upper quartile). Group I (n = 37); Group II (n = 13); Group III (n = 24).a Significantly different from group I (control).
See this image and copyright information in PMC

References

    1. Milla C, Yang S, Cornfield DN, Brennan ML, Hanzen SL, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol. 2004;287:706–714. - PubMed
    1. Armitage JO. Medical progress: bone marrow transplantation. N Engl J Med. 1994;330:827–838. - PubMed
    1. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaun FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M, Beatty PS, Bensinger W, Cheever M, Deeg J, Doney K, Fefer A, Greenberg P, Hansen JA, Hackman R, Hill R, Martin P, Meyers J, Mcguffin R, Neiman P, Sale G, Shulman H, Singer J, Stewart P, Weiden P, Witherspoon R. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 1987;2:243–258. - PubMed
    1. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:686–697. - PubMed
    1. Devetten M, Armitage JO. Hematopoietic cell transplantation: progress and obstacles. Ann Oncol. 2007;18:1450–1456. - PubMed

Publication types